Document Detail

Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented?
MedLine Citation:
PMID:  21749885     Owner:  NLM     Status:  MEDLINE    
Cardiotoxicity remains the limiting factor for many forms of cancer therapy and is the focus of growing research and clinical emphasis. This article outlines the current clinical evidence for left ventricular dysfunction and heart failure for the two most important classes of cardiotoxic chemotherapeutic agents, examines the potential pitfalls that have led to underestimated rates of left ventricular dysfunction from these agents, and reviews strategies for screening for and providing prophylaxis against chemotherapy-associated left ventricular dysfunction.
Ronald M Witteles; Michael B Fowler; Melinda L Telli
Related Documents :
1629005 - Transcatheter closure of ventricular septal defect: a nonsurgical approach to the care ...
2260555 - Central nervous system malformations in the charge association.
858185 - Electrophysiologic delineation of the specialized atrioventricular conduction system in...
8457395 - Morphological variations of fossa ovalis atrial septal defects (secundum): feasibility ...
8445925 - Experience with an implantable tiered therapy device incorporating antitachycardia paci...
23340275 - Cardiac dysfunction in rats prone to audiogenic epileptic seizures.
Publication Detail:
Type:  Journal Article; Review     Date:  2011-05-14
Journal Detail:
Title:  Heart failure clinics     Volume:  7     ISSN:  1551-7136     ISO Abbreviation:  Heart Fail Clin     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-07-13     Completed Date:  2011-12-13     Revised Date:  2013-05-08    
Medline Journal Info:
Nlm Unique ID:  101231934     Medline TA:  Heart Fail Clin     Country:  United States    
Other Details:
Languages:  eng     Pagination:  333-44     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Inc. All rights reserved.
Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Falk CVRC, Stanford, CA 94305, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal, Humanized / administration & dosage,  adverse effects*
Antineoplastic Agents / administration & dosage,  adverse effects
Biomarkers, Pharmacological*
Cardiac Imaging Techniques / methods*
Clinical Trials as Topic
Drug Monitoring / methods*
Neoplasms / drug therapy
Outcome and Process Assessment (Health Care)
Protein Kinase Inhibitors / administration & dosage,  adverse effects
Quinazolines / administration & dosage,  adverse effects*
Severity of Illness Index
Ventricular Dysfunction, Left* / chemically induced,  diagnosis,  epidemiology,  prevention & control
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Antineoplastic Agents; 0/Biomarkers, Pharmacological; 0/Cardiotoxins; 0/Protein Kinase Inhibitors; 0/Quinazolines; 0VUA21238F/lapatinib; P188ANX8CK/trastuzumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherap...
Next Document:  Stem Cell Therapy for Cardiac Disease: What Can Be Learned from Oncology.